137415-99-7Relevant academic research and scientific papers
Smaller, faster, better: Modular synthesis of unsymmetrical ammonium salt-tagged NHC-gold(i) complexes and their application as recyclable catalysts in water
Belger, Katrin,Krause, Norbert
, p. 8556 - 8560 (2015)
Facile access towards a small library of unsymmetrical ammonium salt-tagged N-heterocyclic carbene gold(i) complexes is described, and their application as recyclable catalysts in cyclization reactions of acetylenic carboxylic acids and amides to lactones and lactams, respectively, in aqueous media is demonstrated. Catalyst 1ab was applied in the synthesis of 2-epi-clausemarine A (16).
Iridium-Catalyzed Intramolecular Oxidative Cyclization of Alkenyl Amides and Alkenoic Acids
Nagamoto, Midori,Nishimura, Takahiro,Yorimitsu, Hideki
, p. 4272 - 4282 (2017/09/13)
An iridium/dppf complex efficiently catalyzed the oxidative cyclization of N sulfonyl alkenyl amides and alkenoic acids. Electron deficiena?t alkenes were effective as sacrificial hydrogen acceptors. High selectivity of the oxidative cyclization over the
Bismuth-catalyzed intramolecular hydro-oxycarbonylation of alkynes
Komeyama, Kimihiro,Takahashi, Keita,Takaki, Ken
, p. 602 - 603 (2008/12/21)
Bi(OTf)3 was found to be a good catalyst for intramolecular addition of carboxylic acids to alkynes (hydro-oxycarbonylation), which afforded the corresponding 5- and 6-membered lactones in moderate to good yields under mild conditions. Copyrigh
Transition-metal catalyzed synthesis of δ-hydroxy-γ-lactones from bis(trimethylsilyl) ketene acetals and allylic acetates via γ-unsaturated carboxylic acids. Comments on the formation of α-cyclopropyl carboxylic acids
Rudler, Henri,Harris, Paul,Parlier, Andrée,Cantagrel, Frédéric,Denise, Bernard,Bellassoued, Moncef,Vaissermann, Jacqueline
, p. 186 - 202 (2007/10/03)
Bis(trimethylsilyl)ketene acetals react with allylic acetates in the presence of Pd(0) complexes to give γ-unsaturated carboxylic acids together with α-cyclopropyl carboxylic acids. The unsaturated acids can be converted catalytically to δ-hydroxy-yγ-lactones by the H2O2/MTO system (methyltrioxorhenium) and to butenolides by Pd(II) catalyzed intramolecular cyclization reactions. The structure of two of these lactones has been established by X-ray analysis. The mechanism of the formation of the cyclopropanic acids will be discussed.
Synthesis and antimuscarinic properties of some N-substituted 5- (aminomethyl)-3,3-diphenyl-2(3H)-furanones
Kaiser,Spagnuolo,Adams Jr.,Audia,Dupont,Hatoum,Lowe,Prosser,Sturm,Noronha-Blob
, p. 4415 - 4424 (2007/10/02)
In a study aimed toward developing new, selective antimuscarinic drugs with potential utility in the treatment of urinary incontinence associated with bladder muscle instability, a series of N-substituted 5-(aminomethyl)- 3,3-diphenyl-2(3H)-furanones, conformationally-constrained lactone relatives of benactyzine, was prepared. The compounds were examined in several paradigms that measure muscarinic (M1, M2, and M3) receptor antagonist activity. Selected members of the series that displayed potency and/or selectivity in these tests were studied for their effects on urinary bladder contraction, mydriasis, and salivation in guinea pigs. These studies revealed that incorporation of the amino functionality into an imidazole or pyrazole ring resulted in some novel, potent, and selective antimuscarinic agents. Appropriate alkyl substitution of position 2 of the imidazole strikingly affected muscarinic, particularly M3, receptor activity and may reflect a complementary site of interaction. Some of the compounds selectively reduced bladder pressure in a cystometrogram (CMG) model without producing concomitant mydriatic and salivary effects. The separate and distinct action of several compounds of this series in these in vivo protocols suggests the possibility of subtypes of muscarinic receptors that may correspond to previously characterized molecular cloned subpopulations. In this article, structure-activity relationships for the series of substituted lactones are discussed. These studies led to the identification of (R)-[(2-isopropyl-1H- imidazol-1-yl)methyl]-4,5-dihydro-3,3-diphenyl-2(3H)-furanone (23) as a clinical candidate for treating urinary bladder dysfunction.
